2. Academic Validation
  3. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome

Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome

  • Science. 2006 Apr 7;312(5770):117-21. doi: 10.1126/science.1124287.
Jennifer P Habashi 1,  Daniel P Judge,  Tammy M Holm,  Ronald D Cohn,  Bart L Loeys,  Timothy K Cooper,  Loretha Myers,  Erin C Klein,  Guosheng Liu,  Carla Calvi,  Megan Podowski,  Enid R Neptune,  Marc K Halushka,  Djahida Bedja,  Kathleen Gabrielson,  Daniel B Rifkin,  Luca Carta,  Francesco Ramirez,  David L Huso,  Harry C Dietz
Affiliations

Affiliation

  • 1 Howard Hughes Medical Institute and Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
PMID: 16601194 DOI: 10.1126/science.1124287
Abstract

Aortic aneurysm and dissection are manifestations of Marfan syndrome (MFS), a disorder caused by mutations in the gene that encodes fibrillin-1. Selected manifestations of MFS reflect excessive signaling by the transforming growth factor-beta (TGF-beta) family of cytokines. We show that aortic aneurysm in a mouse model of MFS is associated with increased TGF-beta signaling and can be prevented by TGF-beta antagonists such as TGF-beta-neutralizing antibody or the angiotensin II type 1 receptor (AT1) blocker, losartan. AT1 antagonism also partially reversed noncardiovascular manifestations of MFS, including impaired alveolar septation. These data suggest that losartan, a drug already in clinical use for hypertension, merits investigation as a therapeutic strategy for patients with MFS and has the potential to prevent the major life-threatening manifestation of this disorder.

Figures
Products